FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1919288105> ?p ?o ?g. }

• W1919288105 endingPage "2096" @default.
• W1919288105 startingPage "2090" @default.
• W1919288105 abstract "PURPOSE To assess activity and toxicity of topotecan in previously treated small-cell lung cancer (SCLC) patients. PATIENTS AND METHODS Patients with measurable SCLC, progressive after one first-line regimen, were eligible for the study. Two groups of patients were selected: (1) patients who failed first-line treatment < or = 3 months from chemotherapy discontinuation (refractory group); and (2) patients who responded to first-line treatment and progressed greater than 3 months after chemotherapy discontinuation (sensitive group). Topotecan was administered as a 30-minute daily infusion at a dose of 1.5 mg/m2 for 5 consecutive days, every 3 weeks. RESULTS One hundred one patients were entered onto the study and 403 courses were administered. Ninety-two patients (47 refractory and 45 sensitive) were eligible and assessable for response. Among refractory patients, there were two partial responses (PRs) and one complete response (CR), for an overall response rate of 6.4% (95% confidence interval [CI], 1.3% to 17.6%), whereas in the sensitive group, there were 11 PRs and six CRs, for an overall response rate of 37.8% (95% CI, 23.8% to 53.5%). Overall median duration of response was 7.6 months. Median survival was 5.4 months; median survival of refractory patients was 4.7 months, whereas that of sensitive patients was 6.9 months (P = .002). Median survival of responding patients was 12.5 months. Toxicity was mainly hematologic. Leukopenia, although short-lived, was universal, with grade III and IV neutropenia occurring in 28% and 46.8% of cycles, respectively. Nonhematological toxicity was mild. Fatigue/malaise was reported in 39.3% of cycles and transient elevation of liver enzymes in 17%. CONCLUSION Topotecan has significant activity in SCLC, particularly in patients sensitive to prior chemotherapy, with predictable and manageable toxicity. The incorporation of topotecan in combination chemotherapy regimens for future treatment of SCLC is warranted." @default.
• W1919288105 created "2016-06-24" @default.
• W1919288105 creator A5000286751 @default.
• W1919288105 creator A5002860762 @default.
• W1919288105 creator A5011312455 @default.
• W1919288105 creator A5011819733 @default.
• W1919288105 creator A5018150637 @default.
• W1919288105 creator A5022063365 @default.
• W1919288105 creator A5032116734 @default.
• W1919288105 creator A5032386417 @default.
• W1919288105 creator A5038529742 @default.
• W1919288105 creator A5072294821 @default.
• W1919288105 date "1997-05-01" @default.
• W1919288105 modified "2023-10-15" @default.
• W1919288105 title "Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group." @default.
• W1919288105 cites W132956518 @default.
• W1919288105 cites W1496060302 @default.
• W1919288105 cites W1800874491 @default.
• W1919288105 cites W1942335159 @default.
• W1919288105 cites W1952431753 @default.
• W1919288105 cites W1952453258 @default.
• W1919288105 cites W1981987977 @default.
• W1919288105 cites W1989339760 @default.
• W1919288105 cites W1989811597 @default.
• W1919288105 cites W2020450860 @default.
• W1919288105 cites W2056422898 @default.
• W1919288105 cites W2068403085 @default.
• W1919288105 cites W2077494569 @default.
• W1919288105 cites W2130164889 @default.
• W1919288105 cites W2146653241 @default.
• W1919288105 cites W2167805334 @default.
• W1919288105 cites W2169999184 @default.
• W1919288105 cites W2243395600 @default.
• W1919288105 cites W2260360964 @default.
• W1919288105 cites W2414485598 @default.
• W1919288105 cites W2991531352 @default.
• W1919288105 doi "https://doi.org/10.1200/jco.1997.15.5.2090" @default.
• W1919288105 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9164222" @default.
• W1919288105 hasPublicationYear "1997" @default.
• W1919288105 type Work @default.
• W1919288105 sameAs 1919288105 @default.
• W1919288105 citedByCount "425" @default.
• W1919288105 countsByYear W19192881052012 @default.
• W1919288105 countsByYear W19192881052013 @default.
• W1919288105 countsByYear W19192881052014 @default.
• W1919288105 countsByYear W19192881052015 @default.
• W1919288105 countsByYear W19192881052016 @default.
• W1919288105 countsByYear W19192881052017 @default.
• W1919288105 countsByYear W19192881052018 @default.
• W1919288105 countsByYear W19192881052019 @default.
• W1919288105 countsByYear W19192881052020 @default.
• W1919288105 countsByYear W19192881052021 @default.
• W1919288105 countsByYear W19192881052022 @default.
• W1919288105 countsByYear W19192881052023 @default.
• W1919288105 crossrefType "journal-article" @default.
• W1919288105 hasAuthorship W1919288105A5000286751 @default.
• W1919288105 hasAuthorship W1919288105A5002860762 @default.
• W1919288105 hasAuthorship W1919288105A5011312455 @default.
• W1919288105 hasAuthorship W1919288105A5011819733 @default.
• W1919288105 hasAuthorship W1919288105A5018150637 @default.
• W1919288105 hasAuthorship W1919288105A5022063365 @default.
• W1919288105 hasAuthorship W1919288105A5032116734 @default.
• W1919288105 hasAuthorship W1919288105A5032386417 @default.
• W1919288105 hasAuthorship W1919288105A5038529742 @default.
• W1919288105 hasAuthorship W1919288105A5072294821 @default.
• W1919288105 hasConcept C121332964 @default.
• W1919288105 hasConcept C126322002 @default.
• W1919288105 hasConcept C141071460 @default.
• W1919288105 hasConcept C142424586 @default.
• W1919288105 hasConcept C2776256026 @default.
• W1919288105 hasConcept C2776694085 @default.
• W1919288105 hasConcept C2777063308 @default.
• W1919288105 hasConcept C2778336483 @default.
• W1919288105 hasConcept C2778715236 @default.
• W1919288105 hasConcept C2778822529 @default.
• W1919288105 hasConcept C2780873365 @default.
• W1919288105 hasConcept C2781209748 @default.
• W1919288105 hasConcept C2781413609 @default.
• W1919288105 hasConcept C71924100 @default.
• W1919288105 hasConcept C87355193 @default.
• W1919288105 hasConcept C90924648 @default.
• W1919288105 hasConceptScore W1919288105C121332964 @default.
• W1919288105 hasConceptScore W1919288105C126322002 @default.
• W1919288105 hasConceptScore W1919288105C141071460 @default.
• W1919288105 hasConceptScore W1919288105C142424586 @default.
• W1919288105 hasConceptScore W1919288105C2776256026 @default.
• W1919288105 hasConceptScore W1919288105C2776694085 @default.
• W1919288105 hasConceptScore W1919288105C2777063308 @default.
• W1919288105 hasConceptScore W1919288105C2778336483 @default.
• W1919288105 hasConceptScore W1919288105C2778715236 @default.
• W1919288105 hasConceptScore W1919288105C2778822529 @default.
• W1919288105 hasConceptScore W1919288105C2780873365 @default.
• W1919288105 hasConceptScore W1919288105C2781209748 @default.
• W1919288105 hasConceptScore W1919288105C2781413609 @default.
• W1919288105 hasConceptScore W1919288105C71924100 @default.
• W1919288105 hasConceptScore W1919288105C87355193 @default.
• W1919288105 hasConceptScore W1919288105C90924648 @default.
• W1919288105 hasIssue "5" @default.

• next